1. In Vivo

Medtronic Licenses Early Stage Stent Drug to Prevent Thrombosis

Medtronic has gained rights to ReVas, a drug development program based on novel targets of vascular inflammation, from Resverlogix, for use with drug-eluting stents to prevent thrombosis.

For all the success that drug-eluting stents (DES) have had in preventing restenosis, there is increasing data showing that in a small number of patients, these implants also can produce significant adverse events resulting from late-stage thrombosis. To address that problem, Medtronic Inc. has gained rights to ReVas, a drug development program based on novel targets of vascular inflammation, from Resverlogix Inc.

Donald J. McCaffrey, president and CEO of Calgary, Alberta-based Resverlogix, points out that the two DES currently approved for US...

More from Innovation

More from In Vivo

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.